View more in

Bleb placement change for subretinal gene therapy may prevent guttering

WAILEA, Hawaii — Retinal pigmentary changes were seen in 67% of patients in the phase 1/2 safety study of RGX-314, a gene therapy delivered subretinally for the treatment of AMD. One case was considered severe, and location of the bleb placement may be related. “Pigmentary change is something that’s definitely...